Cited by 407Cannabis and Cannabinoid ResearchParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

The DOI matches its Crossref record; 106 of the 108 references it cites were found in a registry or an index.

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease

Open access

Lastres-Becker, Isabel, Molina-Holgado, Francisco, Ramos, José A., Mechoulam, Raphael, Fernández-Ruiz, Javier·2005·Neurobiology of Disease

DOI 10.1016/j.nbd.2004.11.009

Open this paper in CoChat — free account

Abstract

Cannabinoids have been reported to provide neuroprotection in acute and chronic neurodegeneration. In this study, we examined whether they are also effective against the toxicity caused by 6-hydroxydopamine, both in vivo and in vitro, which may be relevant to Parkinson's disease (PD). First, we evaluated whether the administration of cannabinoids in vivo reduces the neurodegeneration produced by a unilateral injection of 6-hydroxydopamine into the medial forebrain bundle. As expected, 2 weeks after the application of this toxin, a significant depletion of dopamine contents and a reduction of tyrosine hydroxylase activity in the lesioned striatum were noted, and were accompanied by a reduction in tyrosine hydroxylase-mRNA levels in the substantia nigra. None of these events occurred in the contralateral structures. Daily administration of delta9-tetrahydrocannabinol (delta9-THC) during these 2 weeks produced a significant waning in the magnitude of these reductions, whereas it failed to affect dopaminergic parameters in the contralateral structures. This effect of delta9-THC appeared to be irreversible since interruption of the daily administration of this cannabinoid after the 2-week period did not lead to the re-initiation of the 6-hydroxydopamine-induced neurodegeneration. In addition, the fact that the same neuroprotective effect was also produced by cannabidiol (CBD), another plant-derived cannabinoid with negligible affinity for cannabinoid CB1 receptors, suggests that the antioxidant properties of both compounds, which are cannabinoid receptor-independent, might be involved in these in vivo effects, although an alternative might be that the neuroprotection exerted by both compounds might be due to their anti-inflammatory potential. As a second objective, we examined whether cannabinoids also provide neuroprotection against the in vitro toxicity of 6-hydroxydopamine. We found that the non-selective cannabinoid agonist HU-210 increased cell survival in cultures of mouse cerebellar granule cells exposed to this toxin. However, this effect was significantly lesser when the cannabinoid was directly added to neuronal cultures than when these cultures were exposed to conditioned medium obtained from mixed glial cell cultures treated with HU-210, suggesting that the cannabinoid exerted its major protective effect by regulating glial influence to neurons. In summary, our results support the view of a potential neuroprotective action of cannabinoids against the in vivo and in vitro toxicity of 6-hydroxydopamine, which might be relevant for PD. Our data indicated that these neuroprotective effects might be due, among others, to the antioxidant properties of certain plant-derived cannabinoids, or exerted through the capability of cannabinoid agonists to modulate glial function, or produced by a combination of both mechanisms.

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2004.11.009

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The rat brain in stereotaxic coordinates
Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,959
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585
Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.
McCarthy, K. D., & de Vellis, J. (1980) · The Journal of Cell Biology · doi:10.1083/jcb.85.3.890 · Cited by 3,825
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.
Carmichael, J., DeGraff, W., Gazdar, A. F., Minna, J. D., & Mitchell, J. B. (1987) · PubMed · Cited by 3,813
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
Pharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,526
The neostriatal mosaic: multiple levels of compartmental organization
Gerfen, C. R. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90355-c · Cited by 1,471
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315
Self-citation
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease
Blum, D. L., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A., Sadoul, R., & Verna, J. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,269
Transcription-dependent and -independent control of neuronal survival by the PI3K–Akt signaling pathway
Brunet, A., Datta, S. R., & Greenberg, M. E. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00211-7 · Cited by 1,208

Flagged first, then by citations

Show all 108 references

2 of the 108 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 405

Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice
González, S. R., Mena, M. A., Lastres‐Becker, I., Serrano, A., de Yébenes, J. G., Ramos, J. A., & Fernández‐Ruíz, J. (2005) · Brain Research · doi:10.1016/j.brainres.2005.04.010 · Cited by 35
Self-citation
Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease
Wang, M., Liu, H., & Ma, Z. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.832854 · Cited by 36
Inhibition by Anandamide of 6-Hydroxydopamine-Induced Cell Death in PC12 Cells
Mnich, K., Finn, D. P., Dowd, E., & Gorman, A. M. (2010) · International Journal of Cell Biology · doi:10.1155/2010/818497 · Cited by 34
Beneficial and deleterious effects of cannabinoids in the brain: the case of ultra-low dose THC
Sarne, Y. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1578366 · Cited by 34
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
Walther, S., & Halpern, M. (2010) · Pharmaceuticals · doi:10.3390/ph3082689 · Cited by 32
Endocannabinoid Modulation of Dopaminergic Motor Circuits
Morera‐Herreras, T., Miguélez, C., Aristieta, A., Ruíz-Ortega, J. Á., & Ugedo, L. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00110 · Cited by 35
Cannabinoids: Biosynthesis and Biotechnological Applications
Sirikantaramas, S., & Taura, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-54564-6_8 · Cited by 33
Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders
Estrada, J. A., & Contreras, I. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200217140255 · Cited by 33
Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions
Behl, T., Kaur, G., BUNGAU, S. G., Jhanji, R., Kumar, A., Mehta, V., Zengin, G., Brata, R. D., Hassan, S. S. U., & Frățilă, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176235 · Cited by 34
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Burgaz, S., García, C., Gómez‐Cañas, M., Navarrete, C. M., García‐Martín, A., Rolland, A. P., del Río, C., Casarejos, M. J., Muñoz, E. M., Gonzalo‐Consuegra, C., et al. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103583 · Cited by 32
Marijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy
Babayeva, M., Assefa, H., Basu, P., Chumki, S. R., & Loewy, Z. G. (2016) · Parkinson s Disease · doi:10.1155/2016/1279042 · Cited by 38
Cannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactions—A review
Pugazhendhi, A., Suganthy, N., Chau, T. P., Sharma, A. K., Unpaprom, Y., Ramaraj, R., Karuppusamy, I., & Brindhadevi, K. (2021) · Process Biochemistry · doi:10.1016/j.procbio.2021.08.025 · Cited by 32
The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Literature Review of Pre-Clinical Studies
Prakash, S., & Carter, W. G. (2021) · Brain Sciences · doi:10.3390/brainsci11121573 · Cited by 34
Cannabinoids in Late Life Parkinson’s Disease and Dementia: Biological Pathways and Clinical Challenges
Costa, A. C., Joaquim, H. P. G., Pedrazzi, J. F. C., Pain, A. D. O., Duque, G., & Aprahamian, I. (2022) · Brain Sciences · doi:10.3390/brainsci12121596 · Cited by 38
Cannabinoid System in Neurodegeneration: New Perspectives in Alzheimers Disease
Campillo, N. E., & Paez, J. A. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709788167628 · Cited by 31
The arguments for and against cannabinoids application in glaucomatous retinopathy
Panahi, Y., Manayi, A., Nikan, M., & Vazirian, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.106 · Cited by 29
Antimicrobial and Cytotoxic Effects of Cannabinoids: An Updated Review with Future Perspectives and Current Challenges
Saleemi, M. A., Yahaya, N., Zain, N. N. M., Raoov, M., Yong, Y. K., Noor, N. S., & Lim, V. (2022) · Pharmaceuticals · doi:10.3390/ph15101228 · Cited by 29
Sublingual administration of Δ9-tetrahydrocannabinol/β-cyclodextrin complex increases the bioavailability of Δ9-tetrahydrocannabinol in rabbits
Mannila, J., Järvinen, T., Järvinen, K., Tervonen, J., & Jarho, P. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.08.025 · Cited by 29
Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease
Burgaz, S., García, C., Gómez‐Cañas, M., Rolland, A. P., Muñóz, E., & Fernández‐Ruíz, J. (2021) · Molecules · doi:10.3390/molecules26113245 · Cited by 28
Temporal Changes of CB1 Cannabinoid Receptor in the Basal Ganglia as a Possible Structure-Specific Plasticity Process in 6-OHDA Lesioned Rats
Chaves-Kirsten, G. P., Mazucanti, C. H., Real, C. C., de Souza, B. M. B., Britto, L. R. G., & Torrão, A. D. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076874 · Cited by 28
A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ9-Tetrahydrocannabinol
Sultan, S. R., Millar, S., O’Sullivan, S. E., & England, T. J. (2018) · Pharmaceuticals · doi:10.3390/ph11010013 · Cited by 29
Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Török, N., Majláth, Z., Fülöp, F., Toldi, J., & Vécsei, L. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666151222155043 · Cited by 26
Medicinal Cannabis and Central Nervous System Disorders
Ortiz, Y. T., McMahon, L. R., & Wilkerson, J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881810 · Cited by 29
The decrease of dopamine D2/D3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB1 cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D2/D3 antagonist [3H]raclopride and the novel CB1 inverse agonist [125I]SD7015
Farkas, S., Nagy, K., Jia, Z., Harkany, T., Palkovits, M., Donohou, S. R., Pike, V. W., Halldin, C., Máthé, D., Csiba, L., et al. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.02.012 · Cited by 26
Different Approaches, One Target: Understanding Cellular Mechanisms of Parkinson's and Alzheimer's Diseases
Torrão, A. D. S., Café-Mendes, C. C., Real, C. C., Hernandes, M. S., Ferreira, A. F. B., Santos, T. O., Chaves-Kirsten, G. P., Mazucanti, C. H., Ferro, E. S., Scavone, C., et al. (2012) · Brazilian Journal of Psychiatry · doi:10.1016/j.rbp.2012.08.004 · Cited by 27
The Acute Activation of the CB1 Receptor in the Hippocampus Decreases Neurotoxicity and Prevents Spatial Memory Impairment in Rats Lesioned with β-Amyloid 25–35
Patricio-Martínez, A., Sánchez‐Zavaleta, R., Angulo-Cruz, I., Gutierrez-Praxedis, L., Hernández, E. R., Martínez-García, I., & Limón, I. D. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.08.001 · Cited by 27
Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Manera, C., Arena, C., & Chicca, A. (2016) · Recent Patents on CNS Drug Discovery · doi:10.2174/1574889810666160519113853 · Cited by 26
Cannabinoid Receptor Type 1 Agonist ACEA Protects Neurons from Death and Attenuates Endoplasmic Reticulum Stress-Related Apoptotic Pathway Signaling
Vrechi, T. A. D. M., Crunfli, F., Costa, A. P., & Torrão, A. D. S. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9839-1 · Cited by 26
Cannabis in Parkinson’s Disease — the patient’s perspective versus clinical trials: a systematic literature review
Figura, M., Koziorowski, D., & Sławek, J. (2022) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2022.0004 · Cited by 26
Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors
Nader, J., Rapino, C., Gennequin, B., Chavant, F., Francheteau, M., Makriyannis, A., Duranti, A., Maccarrone, M., Solinas, M., & Thiriet, N. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.014 · Cited by 27
A Novel Tetrahydrocannabinol Electrochemical Nano Immunosensor Based on Horseradish Peroxidase and Double-Layer Gold Nanoparticles
Lu, D., Lu, F., & Pang, G. (2016) · Molecules · doi:10.3390/molecules21101377 · Cited by 26
Analysis of natural product regulation of cannabinoid receptors in the treatment of human disease
Badal, S. A. M., Smith, K. N., & Rajnarayanan, R. V. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.06.003 · Cited by 27
The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases
Tudorancea, I. M., Ciorpac, M., Stanciu, G. D., Caratașu, C.-C., Săcărescu, A., Ignat, B. E., Burlui, A., Rezuş, E., Creangă-Murariu, I., Alexa‐Stratulat, T., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102492 · Cited by 28
HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid
Haj, C. G., Sumariwalla, P. F., Hanuš, L., Kogan, N. M., Yektin, Z., Mechoulam, R., Feldmann, M., & Gallily, R. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226100 · Cited by 26
Self-citation
Orchestrated activation of mGluR5 and CB1 promotes neuroprotection
Batista, E. M., Doria, J. G., Ferreira-Vieira, T. H., Alves‐Silva, J., Ferguson, S. S. G., Moreira, F. A., & Ribeiro, F. M. (2016) · Molecular Brain · doi:10.1186/s13041-016-0259-6 · Cited by 25
Phytocannabinoids, CNS cells and development: A dead issue?
Downer, E. J., & Campbell, V. A. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2009.00102.x · Cited by 25
Cannabidiol-treated Rats Exhibited Higher Motor Score After Cryogenic Spinal Cord Injury
Kwiatkoski, M., Guimarães, F. S., & Bel, E. A. D. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9273-8 · Cited by 25
Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors
Jurga, M., Jurga, A., Jurga, K., Kaźmierczak, B., Kuśmierczyk, K., & Chabowski, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011258 · Cited by 30
Drugs of abuse and Parkinson's disease
Mursaleen, L., & Stamford, J. A. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.013 · Cited by 24
Functional effects of cannabinoids during dopaminergic specification of human neural precursors derived from induced pluripotent stem cells
Stanslowsky, N., Jahn, K., Venneri, A., Naujock, M., Haase, A., Martin, U., Frieling, H., & Wegner, F. (2016) · Addiction Biology · doi:10.1111/adb.12394 · Cited by 22
Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims
Engeli, B. E., Lachenmeier, D. W., Diel, P. R., Guth, S., Villar-Fernandez, M., Roth, A., Lampen, A., Cartus, A. T., Wätjen, W., Hengstler, J. G., et al. (2025) · Nutrients · doi:10.3390/nu17030489 · Cited by 23
Research Progress on Cannabinoids in Cannabis (Cannabis sativa L.) in China
Sun, X. (2023) · Molecules · doi:10.3390/molecules28093806 · Cited by 23
Therapeutic considerations of bioactive compounds in Alzheimer's disease and Parkinson's disease: Dissecting the molecular pathways
Phukan, B. C., Roy, R., Gahatraj, I., Bhattacharya, P., & Borah, A. (2023) · Phytotherapy Research · doi:10.1002/ptr.8012 · Cited by 22
Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders
Sampaio, M. D. F. D. S., de Paiva, Y. B., Sampaio, T. B., Pereira, M. G., & Coimbra, N. C. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13997 · Cited by 28
Chemical Composition and In Vitro Neuroprotective Activity of Fibre-Type Cannabis sativa L. (Hemp)
Corsi, L., Pellati, F., Brighenti, V., Plessi, N., & Benvenuti, S. (2018) · Current Bioactive Compounds · doi:10.2174/1573407214666180809124952 · Cited by 22
Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders
Antonazzo, M., Botta, M. F., Bengoetxea, H., Ruíz-Ortega, J. Á., & Morera‐Herreras, T. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.06.012 · Cited by 23
Aplicaciones de los cannabinoides en glaucoma
Pinar‐Sueiro, S., Rodríguez‐Puertas, R., & Vecino, E. (2011) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2010.11.015 · Cited by 21
New insights on endocannabinoid transmission in psychomotor disorders
Giuffrida, A., & Seillier, A. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.002 · Cited by 24
Bioavailability of Δ9-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits
Al-Ghananeem, A. M., Malkawi, A. H., & Crooks, P. A. (2011) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2010.513009 · Cited by 21
Nigrostriatal damage after systemic rotenone and/or lipopolysaccharide and the effect of cannabis
Abdel‐Salam, O. M. E., Omara, E. A. A., El-Shamarka, M. E.-S., & Hussein, J. (2013) · Comparative Clinical Pathology · doi:10.1007/s00580-013-1788-3 · Cited by 21
Cannabinoids in Health and Disease
Meccariello, R., & Chianese, R. (2016) · InTech eBooks · doi:10.5772/61595 · Cited by 22
From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?
de Bitencourt, R. M., Takahashi, R. N., & Carlini, E. A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.638032 · Cited by 23
Protective Effects of Cannabidiol (CBD) against Qxidative Stress, but Not Excitotoxic-Related Neuronal Cell Damage—An In Vitro Study
Jantas, D., Leśkiewicz, M., Regulska, M., Procner, M., Warszyński, P., & Lasoń, W. (2024) · Biomolecules · doi:10.3390/biom14050564 · Cited by 20
Cannabinoid applications in glaucoma
Pinar‐Sueiro, S., Rodríguez‐Puertas, R., & Vecino, E. (2011) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/s2173-5794(11)70004-4 · Cited by 20
Mechanistic insights into the protective effect of paracetamol against rotenone-induced Parkinson’s disease in rats: Possible role of endocannabinoid system modulation
Labib, A. Y., Ammar, R. M., El‐Naga, R. N., El-Bahy, A. A. Z., Tadros, M. G., & Michel, H. E. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107431 · Cited by 20
Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Wilkerson, J. L., Bilbrey, J. A., Felix, J. S., Makriyannis, A., & McMahon, L. R. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173192 · Cited by 20
Exploring the Potential of Cannabinoid Nanodelivery Systems for CNS Disorders
Kolesárová, M., Simko, P., Urbanská, N., & Kisková, T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010204 · Cited by 20
Cannabis Phytochemicals: A Review of Phytocannabinoid Chemistry and Bioactivity as Neuroprotective Agents
Marsh, D. T., & Smid, S. D. (2020) · Australian Journal of Chemistry · doi:10.1071/ch20183 · Cited by 23
Endocannabinoids reduce cerebral damage after hypoxic–ischemic injury in perinatal rats
Lara‐Celador, I., Castro-Ortega, L., Alvarez, A. A., Goñi‐de‐Cerio, F., Prieto, J. L., & Hilario, E. (2012) · Brain Research · doi:10.1016/j.brainres.2012.07.045 · Cited by 19
Cannabinoids, multiple sclerosis and neuroprotection
de Lago, E., Gómez‐Ruíz, M., Moreno‐Martet, M., & Fernández‐Ruíz, J. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.42 · Cited by 19
Interaction of Cannabis Use and Aging: From Molecule to Mind
Yoo, H. B., DiMuzio, J. M., & Filbey, F. M. (2019) · Journal of Dual Diagnosis · doi:10.1080/15504263.2019.1665218 · Cited by 21
Cannabidiol Protects Dopaminergic Neurons in Mesencephalic Cultures against the Complex I Inhibitor Rotenone Via Modulation of Heme Oxygenase Activity and Bilirubin
Duvigneau, J. C., Trovato, A., Müllebner, A., Miller, I., Krewenka, C., Krenn, K., Zich, W., & Moldzio, R. (2020) · Antioxidants · doi:10.3390/antiox9020135 · Cited by 19
The Endocannabinoid System in the Physiology and Pathology of the Basal Ganglia
Gerdeman, G. L., & Fernández‐Ruíz, J. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3_21 · Cited by 19
Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders
Bala, K., Porel, P., & Aran, K. R. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06683-w · Cited by 18
The impact of phyto- and endo-cannabinoids on central nervous system diseases：A review
Zhang, S., Zhang, N.-N., Guo, T., Sheen, L., Ho, C., & Bai, N. (2022) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2022.10.004 · Cited by 18
Cannabidiol Recovers Dopaminergic Neuronal Damage Induced by Reserpine or α-synuclein in Caenorhabditis elegans
Guedes, É. D. C., Erustes, A. G., Leão, A. H. F. F., Carneiro, C. A., Abílio, V. C., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., Bincoletto, C., Smaili, S. S., et al. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03905-z · Cited by 19
Plants, phytochemicals, and natural practices in complementary and alternative system of medicine for treatment of central nervous system disorders
Awuchi, C. G. (2023) · International Journal of Food Properties · doi:10.1080/10942912.2023.2205039 · Cited by 19
How do pinching and plant density affect industrial hemp produced for cannabinoids in open field conditions?
Benevenute, S. D. S., Freeman, J. H., & Yang, R. (2021) · Agronomy Journal · doi:10.1002/agj2.20882 · Cited by 17
Effects of Cannabidiol on Parkinson’s Disease in a Transgenic Mouse Model by Gut-Brain Metabolic Analysis
Zhao, J., Gao, X., Zhao, L., Wang, Y., Zhang, J., & Liu, S. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/1525113 · Cited by 17
Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs
Gioé-Gallo, C., Ortigueira, S., Brea, J. M., Raïch, I., Azuaje, J., Paleo, M. R., Majellaro, M., Loza, M. I., Salas, C. O., Xerardo Garcia-mera, B., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114934 · Cited by 17
Exploring the effects of cannabidiol encapsulation in liposomes on their physicochemical properties and biocompatibility
Jurgelāne, I., Egle, K., Grava, A., Galkina, D., Brante, M., Melnichuks, M., Skrinda-Melne, M., Šalms, Ģ., & Dubņika, A. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2460666 · Cited by 17
Neurotransmitters, Cell Types, and Circuit Mechanisms of Motor Skill Learning and Clinical Applications
Tian, W., & Chen, S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.616820 · Cited by 19
Cannabidiol as an Antioxidant
Borges, R. S., & da Silva, A. B. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00093-4 · Cited by 16
Cannabidiol and its application in the treatment of oral diseases: therapeutic potentials, routes of administration and prospects
Hu, Z., Qin, Z., Xie, J., Qu, Y., & Yin, L. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116271 · Cited by 15
Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Borgonetti, V., Governa, P., Montopoli, M., & Biagi, M. (2019) · Current Bioactive Compounds · doi:10.2174/1573407214666180703130525 · Cited by 15
Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment
Boullon, L., Abalo, R., & Llorente‐Berzal, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.734613 · Cited by 16
Genome-Wide Analysis of Alternative Splicing and Non-Coding RNAs Reveal Complicated Transcriptional Regulation in Cannabis sativa L.
Wu, B., Li, Y., Li, J., Xie, Z., Luan, M., Gao, C., Shi, Y., & Chen, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111989 · Cited by 16
Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders
Kumar, U. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010152 · Cited by 15
A comprehensive update on cannabidiol, its formulations and drug delivery systems
Banerjee, S., Saharan, V. A., Banerjee, D., Ram, V., Kulhari, H., Pooja, D., & Singh, A. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-024-10001-9 · Cited by 16
Unveiling the Potential of Phytocannabinoids: Exploring Marijuana’s Lesser-Known Constituents for Neurological Disorders
Basavarajappa, B. S., & Subbanna, S. (2024) · Biomolecules · doi:10.3390/biom14101296 · Cited by 14
The Endocannabinoid System and Parkinson Disease
Giuffrida, A., & Martinez, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809666-6.00003-4 · Cited by 13
Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models
Morales, P., & Reggio, P. H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57369-0_4 · Cited by 13
P73 and age-related diseases: is there any link with Parkinson Disease?
Grespi, F., & Melino, G. (2012) · Aging · doi:10.18632/aging.100515 · Cited by 12
Parkinson’s disease related alterations in cannabinoid transmission
Soti, M., Ranjbar, H., Kohlmeier, K. A., & Shabani, M. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.11.009 · Cited by 11
Unraveling the Mechanisms of Cannabidiol’s Pharmacological Actions: A Comprehensive Research Overview
Kalsoom, I., Shehzadi, K., Li, H., Wen, H., & Yu, M. (2024) · Topics in Current Chemistry · doi:10.1007/s41061-024-00465-w · Cited by 11
Cannabinoids in Parkinson’s disease
Concannon, R. M., Finn, D. P., & Dowd, E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417041-4.00003-5 · Cited by 11
Cannabinoid receptor 1 contributes to sprouted innervation in endometrial ectopic growth through mitogen-activated protein kinase activation
Han, H., Liang, X., Wang, J., Zhao, Q., Yang, M., Rong, W., & Zhang, G. (2017) · Brain Research · doi:10.1016/j.brainres.2017.03.016 · Cited by 11
Parkinson’s disease, epilepsy, and amyotrophic lateral sclerosis—emerging role of AMPA and kainate subtypes of ionotropic glutamate receptors
Николаевна, В. М., Yen, L. Y., Khmyz, M. I., Sobolevsky, A. I., & Yelshanskaya, M. V. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1252953 · Cited by 9
Anti-Inflammatory Effects of Cannabinoids in Therapy of Neurodegenerative Disorders and Inflammatory Diseases of the CNS
Tomaszewska-Zaremba, D., Gajewska, A., & Misztal, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146570 · Cited by 12
Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis
Urbi, B., Lee, Y., Hughes, I. P., Thorning, S., Broadley, S., Sabet, A., & Heshmat, S. (2022) · BMJ Open Science · doi:10.1136/bmjos-2022-100302 · Cited by 10
The Effects of Chronic Marijuana Administration on 6-OHDA-Induced Learning & Memory Impairment and Hippocampal Dopamine and Cannabinoid Receptors Interaction in Male Rats
Haghparast, E., Sheibani, V., Komeili, G., Chahkandi, M., & Rad, N. S. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03899-8 · Cited by 10
The endocannabinoid system: critical for the neurotrophic action of psychotropic drugs
Hassanzadeh, P. (2010) · Biomedical Reviews · doi:10.14748/bmr.v21.45 · Cited by 10
Antineoplastic and apoptotic effects of cannabinoids. N-acylethanolamines: protectors or killers?
Pushkarev, V. M., Ковзун, О. І., & Tronko, M. D. (2008) · PubMed · Cited by 10
A phosphatidylinositol transfer protein α‐dependent survival factor protects cultured primary neurons against serum deprivation‐induced cell death
Bunte, H., Schenning, M., Sodaar, P., Bär, D., WIRTZ, K. W. A., Muiswinkel, F. L. V., & Snoek, G. T. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03729.x · Cited by 10
Cannabis Use and Cannabidiol Modulate HIV-Induced Alterations in TREM2 Expression: Implications for Age-Related Neuropathogenesis
Avalos, B., Kulbe, J. R., Ford, M. K., Laird, A. E., Walter, K., Mante, M., Florio, J. B., Boustani, A., Chaillon, A., Schlachetzki, J. C. M., et al. (2024) · Viruses · doi:10.3390/v16101509 · Cited by 11
Reversal effect of simvastatin on the decrease in cannabinoid receptor 1 density in 6-hydroxydopamine lesioned rat brains
Mackovski, N., Liao, J., Weng, R., Wei, X., Wang, R., Chen, Z., Liu, X., Yu, Y., Meyer, B. J., Xia, Y., et al. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.05.005 · Cited by 9
Cannabinoids’ Role in Modulating Central and Peripheral Immunity in Neurodegenerative Diseases
Sharon, N., Yarmolinsky, L., Khalfin, B., Fleisher‐Berkovich, S., & Ben‐Shabat, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126402 · Cited by 9
Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model
Silva-Llanes, I., Rodríguez-López, S., González-Naranjo, P., del Sastre, E., López, M. G., Paez, J. A., Campillo, N. E., & Lastres‐Becker, I. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.03.008 · Cited by 8
Self-citation
Cannabinoid receptor ligands prevent dopaminergic neurons death induced by neurotoxic, inflammatory and oxidative stimuli in vitro
Batinga, H. (2016) · Journal of Biomedical Sciencies · doi:10.4172/2254-609x.100016 · Cited by 8
Potential new therapies against a toxic relationship: neuroinflammation and Parkinson’s disease
Rodrigues, L. S., Fagotti, J., Targa, A., Noseda, A. C. D., Ilkiw, J. L., Chuproski, A. P., Dorieux, F. W. C., dos Santos, P. D., & Lima, M. M. S. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000512 · Cited by 8

Authors: Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J.
Affiliations: Universidad Complutense de Madrid (ES)
Hebrew University of Jerusalem (IL)
ORCID: Ramos, José A.
Mechoulam, Raphael
Venue: Neurobiology of Disease
Publisher: Elsevier BV
Published: 2005-06
Volume: 19
Issue: 1-2
Pages: 96-107
ISSN: 0969-9961 (ISSN-L)
DOI: 10.1016/j.nbd.2004.11.009
OpenAlex: W2110514788
Cited by: 407
References: 108
Citations by year: 2026: 8 · 2025: 13 · 2024: 23 · 2023: 25 · 2022: 23 · 2021: 30 · 2020: 29 · 2019: 26 · 2018: 15 · 2017: 26 · 2016: 20 · 2015: 13 · 2014: 13 · 2013: 14 · 2012: 16
FWCI: 12.12
Type: journal article
Language: en
Open access: green
doaj.org
Licence: cc-by-sa
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neurobiology of Disease (publishedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Research Portal (King's College London) (submittedVersion)
Funders: Deakin University
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: cannabinoids, neuroprotection, 6-hydroxydopamine, Parkinson's disease, delta-9-tetrahydrocannabinol, cannabidiol, HU-210, dopamine depletion, tyrosine hydroxylase, substantia nigra, striatum, neuron-glia interactions, cerebellar granule cells
MeSH terms: Animals, Cannabinoids, Cell Survival, Cells, Cultured, Dopamine, Male, Mice, Inbred C57BL, Parkinson Disease, Oxidopamine, Rats, Sprague-Dawley, Neuroprotective Agents, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks